HIV - Technical work
The WHO Department leads the global effort to end the epidemics of HIV, tuberculosis (TB), hepatitis, and sexually transmitted infections (STIs), ensuring that every person has equitable access to highest-quality people-centred scientific evidence and services, regardless of who they are or where they live.
Surveillance of pretreatment HIV drug resistance – populations initiating first-line ART
Pretreatment HIV drug resistance is detected among people
initiating antiretroviral therapy (ART) with or without prior antiretroviral
drug exposure. It can result from transmitted or acquired HIV drug resistance,
or both. Surveillance of the pre-treatment HIV drug resistance survey in
populations initiating first-line ART is relevant to inform the choice of
nationally recommended first-line ART regimens, and also regimens used for pre-
and post-exposure prophylaxis.
Concept note
Toolkit: implementation of the survey of pretreatment HIV drug resistance
52 KB
104 KB
WHO regularly produces a global report on HIV drug resistance threats, prevalence and trends, based on the information shared by countries. Click here to see the reports.